Cellectar Biosciences, Inc., a prominent clinical biopharmaceutical firm, announced its mission to revolutionize cancer treatment by pioneering the discovery, development, and commercialization of innovative medications. Its groundbreaking Phospholipid Drug Conjugate (PDC) compound, CLR 131 (iopofosine I-131), is currently in its Phase 2 clinical study, with applications for B-cell malignancies, relapsed or refractory Waldenstrom's macroglobulinemia cohort, multiple myeloma, and non-Hodgkin's lymphoma. Additionally, the company is conducting a Phase 1 clinical study for pediatric patients with select solid tumors, lymphomas, malignant brain tumors, and head and neck cancer. Cellectar Biosciences is devoted to developing and carrying out its ambitious PDC Chemotherapeutic program, CLR 1900, for solid tumors, which is currently in preclinical development stages, with collaborative efforts alongside Orano Med to advance its CLR 12120 Series and partnering with LegoChemBio. Founded in 2002, Cellectar Biosciences is headquartered in Florham Park, New Jersey.
Cellectar Biosciences, Inc.'s ticker is CLRB
The company's shares trade on the NASDAQ stock exchange
They are based in Florham Park, New Jersey
There are 1-10 employees working at Cellectar Biosciences, Inc.
It is https://www.cellectar.com/
Cellectar Biosciences, Inc. is in the Healthcare sector
Cellectar Biosciences, Inc. is in the Biotechnology industry
The following five companies are Cellectar Biosciences, Inc.'s industry peers: